PCRX
Pacira BioSciences Inc. Healthcare - Biotechnology Investor Relations →
Pacira BioSciences Inc. (PCRX) closed at $22.11 as of 2026-03-20, trading 30.2% below its 200-week moving average of $31.68. This places PCRX in the extreme value zone. The stock is currently moving closer to the line, down from -27.1% last week. The 14-week RSI sits at 37, indicating neutral momentum.
Trading volume is running at 1.6x of its 14-week average, which is in the normal range. The balance between buying and selling volume (0.73 ratio) is neutral — neither side is clearly dominating.
Over the past 741 weeks of data, PCRX has crossed below its 200-week moving average 10 times. On average, these episodes lasted 38 weeks. Historically, investors who bought PCRX at the start of these episodes saw an average one-year return of +13.3%.
With a market cap of $951 million, PCRX is a small-cap stock. The company generates a free cash flow yield of 11.4%, which is notably high. Return on equity stands at 1.0%. The stock trades at 1.3x book value.
The company has been aggressively buying back shares, reducing its share count by 10.5% over the past three years. This stock also meets the Yartseva multibagger criteria as a small-cap with strong free cash flow yield and reasonable book value.
Over the past 14.2 years, a hypothetical investment of $100 in PCRX would have grown to $206, compared to $634 for the S&P 500. PCRX has returned 5.2% annualized vs 13.8% for the index, underperforming the broader market over this period.
Free cash flow has been growing at a 5.9% compound annual rate, with 4 consecutive years of positive cash generation. A business generating more cash every year while trading below its 200-week moving average is exactly the kind of disconnect value investors look for.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: PCRX vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After PCRX Crosses Below the Line?
Across 10 historical episodes, buying PCRX when it crossed below its 200-week moving average produced an average return of +14.0% after 12 months (median -7.0%), compared to +21.5% for the S&P 500 over the same periods. 40% of those episodes were profitable after one year. After 24 months, the average return was +49.5% vs +52.1% for the index.
Each line shows $100 invested at the moment PCRX crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
PCRX has crossed below its 200-week MA 10 times with an average 1-year return of +13.3% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Jan 2012 | Jan 2012 | 2 | 12.9% | +139.3% | +176.7% |
| Sep 2015 | Nov 2015 | 6 | 22.6% | -22.6% | -53.6% |
| Feb 2016 | Apr 2016 | 6 | 15.7% | -22.4% | -60.5% |
| Apr 2016 | Apr 2019 | 157 | 50.7% | -10.3% | -59.1% |
| May 2019 | Jul 2019 | 10 | 7.9% | -5.2% | -49.4% |
| Aug 2019 | Nov 2019 | 13 | 16.7% | +37.4% | -47.9% |
| Mar 2020 | May 2020 | 9 | 24.0% | +72.5% | -44.9% |
| Aug 2022 | Sep 2022 | 1 | 2.4% | -31.3% | -57.2% |
| Sep 2022 | Sep 2022 | 1 | 0.4% | -37.3% | -58.2% |
| Oct 2022 | Ongoing | 180+ | 76.1% | Ongoing | -57.2% |
| Average | 38 | — | +13.3% | — |
Frequently Asked Questions
Is PCRX below its 200-week moving average?
Yes. As of 2026-03-20, Pacira BioSciences Inc. (PCRX) is trading 30.2% below its 200-week moving average of $31.68. The current price is $22.11.
What is PCRX's 200-week moving average price?
Pacira BioSciences Inc.'s 200-week moving average is $31.68 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when PCRX drops below its 200-week moving average?
PCRX has crossed below its 200-week moving average 10 times in our data. On average, buying at that moment produced a one-year return of +13.3%. These dips have historically been decent entry points. These episodes lasted 38 weeks on average.
Is PCRX a good value right now?
Here's what our data says about PCRX as of 2026-03-20: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 37. Free cash flow yield is 11.4%. Return on equity is 1.0%. Price-to-book is 1.3x. This is not a buy or sell recommendation — always do your own research.
How does PCRX compare to the S&P 500?
Over the past 14.2 years, $100 invested in PCRX would have grown to $206, compared to $634 for the S&P 500. That's 5.2% annualized vs 13.8% for the index. PCRX has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-03-20